KURA Kura Oncology Inc.

Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH

Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH
EN
07/10/2020

Underlying

KURAKura Oncology Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kura Oncology Inc.

 PRESS RELEASE
Free
KURA Kura Oncology ...

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635...

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on November 3, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 21,750 shares of common stock to a new non-executive employee under the Comp...

November 7, 2025 1 EN
Wedbush Research
  • Wedbush Research
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
QLYS QUALYS INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
CTMX CYTOMX THERAPEUTICS INC.
AXTI AXT INC.
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EGHT 8X8 INC.
ANAB ANAPTYSBIO INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
PINS PINTEREST INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
CRSR INC.
VRDN CORSAIR GAMING
IMNM VIRIDIAN THERAPEUTICS INC
DAWN IMMUNOME
XMTR DAY ONE BIOPHARMACEUTICALS INC
TNGX XOMETRY
STX INC.
HOWL TANGO THERAPEUTICS
RIVN INC
GFS SEAGATE TECHNOLOGY HLDGS PLC
CMPX WEREWOLF THERAPEUTICS INC
SYRE RIVIAN AUTOMOTIVE INC
BCAX GLOBALFOUNDRIES INC
CBIO COMPASS THERAPEUTICS
SPYRE THERAPEUTICS INC.
BICARA THERAPEUTICS INC.
CRESCENT BIOPHARMA INC.
11/05/25 November 5, 2025 1 EN
Geoffrey Von Der Ahe ... (+3)
  • Geoffrey Von Der Ahe
  • Ritika Das
  • Robert Driscoll
KURA KURA ONCOLOGY INC.
11/04/25 November 4, 2025 1 EN
 PRESS RELEASE
Free
KURA Kura Oncology ...

Kura Oncology Reports Third Quarter 2025 Financial Results

Kura Oncology Reports Third Quarter 2025 Financial Results – New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 – – KOMET 017 Phase 3 trials to evaluate ziftomenib in combination with intensive and non-intensive chemotherapy in frontline AML are accelerating; ziftomenib being investigated in settings representing more than 50% of AML patients – – Two oral presentations at 2025 ASH Annual Meeting on ziftomenib in combination with venetoclax / azacitidine chemotherapy in frontline and R/R ...

November 4, 2025 1 EN
 PRESS RELEASE
Free
KURA Kura Oncology ...

Kura Oncology Receives Second $30 Million Development Milestone Paymen...

Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin – Milestone triggered by dosing of first patient in the second of two frontline AML Phase 3 clinical trials – SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced receipt of a $30 million milestone payment under its collaboration agreement with Kyowa Kirin in connection with the dosing of the first...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch